Adapted physical activity programs for the prevention and treatment of musculoskeletal pain induced by aromatase inhibitors in non-metastatic breast cancer patient: A scoping review

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-11-01 DOI:10.1016/j.critrevonc.2024.104548

Nathalie Piazzon , Marion Cortet , Elise Vérot , Florence Carrouel

{"title":"Adapted physical activity programs for the prevention and treatment of musculoskeletal pain induced by aromatase inhibitors in non-metastatic breast cancer patient: A scoping review","authors":"Nathalie Piazzon , Marion Cortet , Elise Vérot , Florence Carrouel","doi":"10.1016/j.critrevonc.2024.104548","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Aromatase inhibitor is associated with a high incidence of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in postmenopausal women with hormone-sensitive breast cancer.</div></div><div><h3>Objective</h3><div>This scoping review aims to identify available information regarding the frameworks, models, or strategies of adapted physical activity (APA) programs implemented for the prevention and management of AIMSS.</div></div><div><h3>Methods</h3><div>Search was realized by two independent reviewers in six databases following PRISMA-ScR guidelines. Data of included articles were extracted, and risk of bias analyzed.</div></div><div><h3>Results</h3><div>Finally, 14 were included. No study has examined APA in the prevention of AIMSS. There is no solid evidence supporting the impact of APA on the management of AIMSS. However, evidence suggests that an APA program can reduce the worst joint pain and improve the quality of life.</div></div><div><h3>Conclusion</h3><div>Future research will enlighten clinical practices with the development of personalized APA programs in hormone-sensitive breast cancer.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104548"},"PeriodicalIF":5.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002919","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Aromatase inhibitor is associated with a high incidence of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in postmenopausal women with hormone-sensitive breast cancer.

Objective

This scoping review aims to identify available information regarding the frameworks, models, or strategies of adapted physical activity (APA) programs implemented for the prevention and management of AIMSS.

Methods

Search was realized by two independent reviewers in six databases following PRISMA-ScR guidelines. Data of included articles were extracted, and risk of bias analyzed.

Results

Finally, 14 were included. No study has examined APA in the prevention of AIMSS. There is no solid evidence supporting the impact of APA on the management of AIMSS. However, evidence suggests that an APA program can reduce the worst joint pain and improve the quality of life.

Conclusion

Future research will enlighten clinical practices with the development of personalized APA programs in hormone-sensitive breast cancer.

查看原文本刊更多论文

预防和治疗非转移性乳腺癌患者因芳香化酶抑制剂引起的肌肉骨骼疼痛的适应性体育活动计划：范围界定综述。

背景：在患有激素敏感性乳腺癌的绝经后妇女中，芳香化酶抑制剂与芳香化酶抑制剂相关肌肉骨骼综合征（AIMSS）的发病率很高：本综述旨在确定有关为预防和管理 AIMSS 而实施的适应性体力活动（APA）计划的框架、模式或策略的现有信息：方法：由两名独立审稿人按照 PRISMA-ScR 指南在六个数据库中进行检索。结果：最终有 14 篇文章被收录：最后，共收录了 14 篇文章。没有一项研究探讨了 APA 在预防 AIMSS 方面的作用。没有确凿证据支持 APA 对 AIMSS 管理的影响。不过，有证据表明，APA 计划可以减轻最严重的关节疼痛，提高生活质量：未来的研究将为激素敏感型乳腺癌患者制定个性化的 APA 方案，为临床实践提供启示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.